Bayesian methods for the design and analysis of noninferiority trials

References

• Albers, G. W., Diener, H. C., Frison, L., Grind, M., Nevinson, M., Partridge, S., Halperin, J. L., Horrow, J., Olsson, S. B., Petersen, P., Vahanian, A. (2005). Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial. JAMA 293:690–698.
   PubMed Web of Science ®Google Scholar
• Birnbaum, A. (1962). On the foundations of statistical inference (with discussion). Journal of the American Statistical Association 57:269–326.
   Web of Science ®Google Scholar
• Blackwelder, W. (1982). “Proving the null hypothesis” in clinical trials. Controlled Clinical Trials 3:345–353.
   PubMedGoogle Scholar
• Burger, H., Beyer, U., Abt, M. (2011). Issues in the assessment of non-inferiority: Perspectives drawn from case studies. Pharmaceutical Statistics 10:433–439.
   PubMed Web of Science ®Google Scholar
• Chang, M. (2007). Multiple-arm superiority and non-inferiority designs with various end-points. Pharmaceutical Statistics 6:43–52.
   PubMed Web of Science ®Google Scholar
• Chen, M. H., Ibrahim, J. G., Lamm, P., Zhang, Y. (2011). Bayesian design of non-inferiority trials for medical devices using historical data. Biometrics 67:1163–1170.
   PubMed Web of Science ®Google Scholar
• D’Agostino, R. B. S., Massaro, J. M., Sullivan, L. M. (2003). Non-inferiority trials: design concepts and issues – the encounters of academic consultants in statistics. Statistics in Medicine 22:169–186.
   PubMed Web of Science ®Google Scholar
• Daimon, T. (2008). Bayesian sample size calculations for a non-inferiority test of two proportions in clinical trials. Contemporary Clinical Trails 29:507–516.
   PubMed Web of Science ®Google Scholar
• Durrleman, S., Chaikin, P. (2003). The use of putative placebo in active control trials: Two applications in a regulatory setting. Statistics in Medicine 22:941–952.
   PubMed Web of Science ®Google Scholar
• EMA (2005). Guideline on the choice of non-inferiority margin. EMEA/CPMP/EWP/2158/99. URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003636.pdf
   Google Scholar
• FDA (2010). Draft Guidance for industry: Non-inferiority clinical trials. Center for Biologics Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services.
   Google Scholar
• Fisher, L., Gent, M., Bller, H. (2001). Active-control trials: How would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. American Hearth Journal 141:26–32.
   PubMed Web of Science ®Google Scholar
• Fleming, T. (2008). Current issues in non-inferiority trials. Statistics in Medicine 27:317–332.
   PubMed Web of Science ®Google Scholar
• Gamalo, M., Wu, R., Tiwari, R. (2011). Bayesian approach to noninferiority trials for proportions. Journal of Biopharmaceutical Statistics 21:902–919.
   PubMed Web of Science ®Google Scholar
• Gamalo, M., Wu, R., Tiwari, R. (2012). Bayesian approach to non-inferiority trials for normal means. Statistical Methods in Medical Research May 21(Epub).
   PubMed Web of Science ®Google Scholar
• Gamalo, M., Tiwari, R., LaVange, L. (2013). Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products. Pharmaceutical Statistics 13:25–40.
   PubMed Web of Science ®Google Scholar
• Gould, A. (1991). Another view of active-controlled trials. Controlled Clinical Trials 12:474–485.
   PubMedGoogle Scholar
• Gsteiger, S., Neuenschwander B., Mercier, F., Schmidli, H. (2013). Using historical control information for the design and analysis of clinical trials with over-dispersed count data. Statistics in Medicine 32:3609–3622.
   PubMed Web of Science ®Google Scholar
• Hasselblad, V., Kong, D. (2001). Statistical methods for comparison to placebo in active-control trials. Drug Information Journal 35:435–449.
   Web of Science ®Google Scholar
• Higgins, J., Whitehead, A. (1996). Borrowing strength from external trials in a meta-analysis. Statistics in Medicine 15:2733–2749.
   PubMed Web of Science ®Google Scholar
• Hobbs, B. P., Sargent, D. J., Carlin, B. P. (2012). Commensurate priors for incorporating historical information in clinical trials using general and generalized linear models. Bayesian Analysis 7:639–674.
   PubMed Web of Science ®Google Scholar
• Hung, H., Wang, S., O’Neill, R. (2009). Challenges and regulatory experiences with non-inferiority trial design without placebo arm. Biometrical Journal 51:324–334.
   PubMed Web of Science ®Google Scholar
• Ibrahim, J., Chen, M. (2000). Power prior distributions for regression models. Statistical Science 15:46–60.
   Web of Science ®Google Scholar
• ICH. (2000). E10 Choice of control group in clinical trials. CPMP/ICH/364/96.
   Google Scholar
• Julious, S., Owen, R. (2011). A comparison of methods for sample size estimation for non-inferiority studies with binary outcomes. Statistical Methods in Medical Research 20:595–612.
   PubMed Web of Science ®Google Scholar
• Julious, S. (2011). Seven useful designs. Pharmaceutical Statistics 11:24–31.
   PubMed Web of Science ®Google Scholar
• Kawasaki, Y., Miyaoka, E. (2012). A Bayesian non-inferiority test for two independent binomial proportions. Pharmaceutical Statistics 12:201–206.
   Web of Science ®Google Scholar
• Kirby, S., Burke, J., Chuang-Stein, C., Sin, C. (2012). Discounting phase 2 results when planning phase 3 clinical trials. Pharmaceutical Statistics 11:373–385.
   PubMed Web of Science ®Google Scholar
• Liang, K., Zeger, S. (2000). Longitudinal data analysis of continuous and discrete responses for pre-post designs, Sankhyā: The Indian Journal of Statistics, Series B 62:134–148.
   Google Scholar
• Liu, G., Lu, K., Mogg, R., Mallick, M., Mehrotra, D. (2009). Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials? Statistics in Medicine 28:2509–2530.
   PubMed Web of Science ®Google Scholar
• Lu, G., Ades, A. (2004). Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine 23:3105–3124.
   PubMed Web of Science ®Google Scholar
• Miettinen, O., Nurminen, M. (1985). Comparative analysis of two rates. Statistics in Medicine 4:213–216.
   PubMed Web of Science ®Google Scholar
• Neuenschwander, B., Capkun-Niggli, G., Branson, M., Spiegelhalter, D. (2010). Summarizing historical information on controls in clinical trials. Clinical Trials 7:5–18.
   PubMed Web of Science ®Google Scholar
• Neuenschwander, B., Rouyrre, N., Hollaender, N., Zuber, E., Branson, M. (2011). A proof of concept phase II non-inferiority criterion. Statistics in Medicine 30:1618–1627.
   PubMed Web of Science ®Google Scholar
• Newcombe, R. (1998). Interval estimation for the difference between independent proportions: Comparison of eleven methods. Statistics in Medicine 17:873–890.
   PubMed Web of Science ®Google Scholar
• Osman, M., Ghosh, S. (2011). Semiparametric Bayesian testing procedure for non-inferiority trials with binary endpoints. Journal of Biopharmaceutical Statistics 21:920–937.
   PubMed Web of Science ®Google Scholar
• Pocock, S. (1976). The combination of randomized and historical controls in clinical trials. J. Chronic. Dis. 29:175–188.
   PubMedGoogle Scholar
• Price, K., LaVange, L. (2014). Bayesian methods in medical product development and regulatory reviews. Pharmaceutical Statistics 13:1–2.
   PubMed Web of Science ®Google Scholar
• Reyes, E., Ghosh, S. (2013). Bayesian average error-based approach to sample size calculations for hypothesis testing. Journal of Biopharmaceutical Statistics 23:569–588.
   PubMed Web of Science ®Google Scholar
• Rothman, K., Michels, K. (1994). The continuing unethical use of placebo controls. The New England Journal of Medicine 331:394–398.
   PubMed Web of Science ®Google Scholar
• Rothmann, M., Li, N., Chen, G., Chi, G. Y., Temple, R., Tsou, H. H. (2003). Design and analysis of non-inferiority mortality trials in oncology. Statistics in Medicine 22:239–264.
   PubMed Web of Science ®Google Scholar
• Salanti, G., Higgins, J., Ades, A., Ioannidis, J. (2008). Evaluation of networks of randomized trials. Statistical Methods in Medical Research 17:279–301.
   PubMed Web of Science ®Google Scholar
• Schmidli, H., Wandel, S., Neuenschwander, B. (2013). The network meta-analytic-predictive approach to non-inferiority trials. Statistical Methods in Medical Research 22:219–240.
   PubMed Web of Science ®Google Scholar
• Schmidli, H., Gsteiger, S., Roychoudhury, S., O’Hagan, A., Spiegelhalter, D., Neuenschwander, B. (2014). Robust meta-analytic-predictive priors in clinical trials with historical control information. Biometrics 70:1023–1032.
   PubMed Web of Science ®Google Scholar
• Simon, R. (1999). Bayesian design and analysis of active control clinical trials. Biometrics 55:484–487.
   PubMed Web of Science ®Google Scholar
• Snapinn, S. (2004). Alternatives for discounting in the analysis of noninferiority trials. Journal of Biopharmaceutical Statistics 14:63–273.
   Google Scholar
• Snapinn, S., Jiang, Q. (2008). Preservation of effect and the regulatory approval of new treatments on the basis of noninferiority trials. Statistics in Medicine 27:382–391.
   PubMed Web of Science ®Google Scholar
• Spiegelhalter, D. J., Abrams, K. R., Myles, J. P. (2004). Bayesian Approaches to Clinical Trials and Health-Care Evaluation. New York: Willey & Sons.
   Google Scholar
• Temple, R., Ellenberg, S. S. (2000). Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Annals of Internal Medicine 133:455–463.
   PubMed Web of Science ®Google Scholar
• Wellek, S. (2005). Statistical methods for the analysis of two-arm non-inferiority trials with binary outcomes. Biometrics 47:48–61.
   Web of Science ®Google Scholar
• Williamson, P.P. (2007). Bayesian equivalence testing for binomial random variables. Journal of Statistical Computation and Simulation 77:739–755.
   Web of Science ®Google Scholar
• Witte, S., Schmidli, H., O’Hagan, A., Racine, A. (2011). Designing a non-inferiority study in kidney transplantation: A case study. Pharmaceutical Statistics 10:427–432.
   PubMed Web of Science ®Google Scholar